Markets

Insider Trading

Hedge Funds

Retirement

Opinion

1281292 - 11759070 - 1

Top 15 Pharmaceuticals Companies in India

In this article, we will take a look at the top 15 pharmaceutical companies in India. For more companies, click Top 5 Pharmaceutical Companies in India.

India is the largest producer of generic medications and vaccines worldwide. It makes up about 20% of the entire amount of generic drug supply in the world. With almost 200 nations receiving Indian pharmaceutical exports, India is a significant pharmaceutical exporter.

In addition, India has a strong network of over 10,500 production facilities, over 3,000 pharmaceutical enterprises, and a manpower pool that is highly skilled. Outside of the US, India has the most pharmaceutical manufacturing facilities that adhere to FDA rules.

More than 500 active pharmaceutical ingredients (APIs) are produced in India, supplying 60,000 generic brands. India now has the third-largest API market in the world as a result. Most supplies are made up of over-the-counter medications used to treat common ailments without endangering life. The pharmaceutical industry’s most important cities are Mumbai, Bangalore, Hyderabad, Pune, Visakhapatnam, and Ahmedabad.

One of the top-performing sectors that provide lucrative business prospects is the Indian pharmaceutical market. In recent years, it has experienced enormous expansion. As the Indian pharmaceutical business transitions from a volume maker to a valued supplier in 2022, investors are turning to this sector for safe haven investments. 

In 2020, the pharmaceutical industry’s main focus was on covid medicines, but by 2022, it had turned to other serious ailments, including cancer and anaemia. In addition, research and development were highly valued in the Indian pharmaceutical business. As a result, India emerged as a global medical behemoth’ in 2022 by growing its R&D ecosystem and increasing pharmaceutical exports. 

India’s pharmaceutical sector is presently worth $50 billion. A recent EY FICCI analysis projects that the Indian pharmaceutical industry will expand to $65 billion by 2024 and to $130 billion by 2030 due to a growing consensus over the need to provide patients with novel, innovative remedies. By 2023, it is anticipated that the worldwide market for pharmaceutical products will reach $1 trillion. With this outlook in mind, let’s start our list of top pharmaceuticals company in India.

Our Methodology

This article will examine the biggest pharma companies in India. The companies are listed in ascending order of total employee count because larger enterprises often have a far higher staff count than smaller ones in the same industry.

Top Pharmaceuticals Companies in India

15. Intas Pharmaceuticals Limited

Number of Employees: 8,000 

Intas Pharmaceuticals Limited is an Indian pharmaceutical company headquartered in Ahmedabad. It produces generic medications as well as contracts clinical research and production. It operates 18 production sites, 15 of which are in India and the remainder in the United Kingdom and Mexico. Intas has a presence in more than 85 countries and is expanding at a CAGR of over 22%.

14. Emcure Pharmaceuticals

Number of Employees: 9,000

Emcure Pharmaceuticals Limited is a multinational pharmaceutical firm based in Pune, India. Emcure’s product line includes tablets, capsules, and injectables. Emcure Pharmaceuticals’ product portfolio, which has a strong chronic and sub-chronic emphasis, includes all the key medicines and is the industry leader in fields including women’s health, blood-related illnesses, HIV, anti-infectives, cardiac care, and vitamins. Emcure Pharmaceuticals has distribution channels and a network that reaches over 70 countries. In addition, the company has 14 production plants and 5 R&D centers. Emcure Pharmaceuticals Limited generated revenue of $730 million in FY 2022. 

13. Piramal Enterprises Limited (NSE:PEL.NS)

Number of Employees: 13,561

Piramal Enterprises Limited conducts operations in the financial services and pharmaceutical industries in India, North America, Europe, Japan, and other countries. Financial Services and Pharmaceuticals Manufacturing and Services are two of its operating segments. The business provides contract development and manufacturing services, such as drug discovery, production, and manufacturing of active pharmaceutical ingredients and formulations, as well as drugs for intrathecal spasticity management, inhalation and injectable anesthesia, injectable pain, antibiotics, and other medications. 

12. Torrent Pharmaceuticals Limited (NSE:TORNTPHARM.NS)

Number of Employees: 13,900

Torrent Pharmaceuticals Limited is the main company of the Torrent Group and is one of the leading Pharma companies in India. The firm is among the leaders in the therapeutic area of cardiovascular, central nervous system, gastrointestinal, and women’s healthcare. Torrent Pharmaceuticals Limited in India originally introduced the idea of specialty marketing. The company is also well-represented in cancer, anti-infectives, diabetology, and pain treatment categories. Additionally, Torrent Pharma has a significant global footprint that spans 40 nations, with activities in developed and rising areas such as the US, Europe, Brazil, and the rest of the globe. The company operates through its 12 fully-owned subsidiaries, having a presence in 40 countries. In 2022, the company’s revenue was $1.1 billion.

11. Abbott India Limited (NSE:ABBOTINDIA.NS)

Number of Employees: 14,000

Abbott India Limited, located in Mumbai, is a publicly traded corporation and a subsidiary of Abbott Capital India Limited. It has one of the quickest rates of growth among Indian pharmaceutical businesses. The business offers trustworthy, high-quality drugs in various therapeutic areas, such as women’s health, gastroenterology, cardiology, metabolic disorders, central nervous system, pain management, pre-term labor, vitamins, sleeplessness, vaccinations, consumer health, etc. Thyronorm, Eptoin, Duphaston, Duphalac, Vertin, Udiliv, Heptral, Digene, Cremaffin, and Prothiaden are some of its well-known trademarks.

10. Biocon Limited (NSE:BIOCON.NS)

Number of Employees: 14,750

Biocon Limited (NSE:BIOCON.NS) makes drugs, therapeutic compounds, and herbal items. Generics, Novel Biologics, Biosimilars, and Research Services are among the company’s segments. Its primary focus areas include diabetes, cancer, immunology, ophthalmology, and bone health issues. It also offers comprehensive services for the research, development, and manufacture of both small and large molecules. The company provides customer assistance in around 120 countries, including Europe and the US. INSUGEN (rh-insulin), BASALOG (Glargine), BIOMAb EGFR (Nimotuzumab), BLISTO (Glimepiride + Metformin), CANMAb (Trastuzumab), Evertor (Everolimus), TACROGRAF (Tacrolimus), ALZUMAb (Itolizumab), and KRABEVA (Bevacizumab) are some of Biocon’s most important brands in India. The company’s consolidated revenue grew 14% to $1.1 billion in FY22.

9. Glenmark Pharmaceuticals Limited (NSE:GLENMARK.NS)

Number of Employees: 15,415

Glenmark Pharmaceuticals Limited develops, produces, and markets pharmaceutical products in India, North America, Latin America, Europe, Japan, and globally through its subsidiaries. In the therapeutic fields of dermatology, respiratory, and cancer, the firm offers both branded and generic formulations and different active pharmaceutical components. The company operates 14 production plants in Argentina, the Czech Republic, India, and the US. Numerous regulatory agencies inspect these facilities, such as the US-FDA, MHRA UK, and ANVISA Brazil. In addition, being a research-driven company, Glenmark Pharmaceuticals Limited has also made investments in special R&D facilities for international markets. Glenmark Pharmaceuticals Limited brought in $1.48 billion in sales in FY 2022.

8. Alkem Laboratories Ltd. (NSE:ALKEM.NS)

Number of Employees: 17,000

Alkem Laboratories is a pharmaceutical company with international operations. The business creates, produces, and markets pharmaceutical and nutraceutical goods. It has built a strong market position in anti-infective, gastrointestinal, pain management, vitamins, minerals, and nutritional areas, as well as acute treatment. Branded Generics, Generic Drugs, API Nutraceuticals, and Biosimilars are among the company’s product offerings. As of March 31, 2022, Alkem had 21 production facilities—19 in India and 2 in the US. Clavam, Pan 40, Taxim-O, Taxim-D, Taxim Injection, Gemcal, A to Z Tabs, Ondem, Xone, Sumo, Zocef, Pipzo, Swich, Xone XP, and Uprise D3 are some of its top brands.

7. Divi’s Laboratories (NSE:DIVISLAB:NS)

Number of Employees: 17000

Established in 1990, Divi’s Laboratories is a top producer of active pharmaceutical ingredients, exporting top-notch goods to over 95 nations. Europe accounts for most of the company’s sales, followed by North America, India, and Asia. The business views investing in mergers and acquisitions as a possible part of its operational growth plan to boost its R&D, production, and marketing capabilities. In FY22, Divi’s Laboratories generated $1.1 billion in revenue.

6. Lupin Limited (NSE:LUPIN.NS)

Number of Employees: 20,000

Lupin Limited develops, produces, distributes, and markets a wide range of biotechnology products, branded and generic formulations, and active pharmaceutical ingredients (APIs). Cardiovascular, asthma, diabetes management, pediatrics, central nervous system, gastroenterology, anti-infectives, nonsteroidal anti-inflammatory medications (NSAIDs), anti-TB, and cephalosporins are among its areas of specialization. With 18 production facilities, Lupin sells its goods in more than 100 nations. India, the US, Japan, Europe, South Africa, the Philippines, and Australia are key markets for the company. The Indian pharmaceutical firm Lupin Limited announced net revenues of $1.96 billion for the fiscal year 2022.

Click to continue reading and see Top 5 Pharmaceuticals Company in India.

Suggested articles:

Disclosure: None. Top 15 Pharmaceuticals Company in India is originally published on Insider Monkey.

The $250 Trillion AI Hype is Real. A few years from now, you’ll probably wish you’d bought this stock.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

When Jeff Bezos said that one breakthrough technology would shape Amazon’s destiny, even Wall Street’s biggest analysts were caught off guard.

Fast forward a year and Amazon’s new CEO Andy Jassy described generative AI as a “once-in-a-lifetime” technology that is already being used across Amazon to reinvent customer experiences.

At the 8th Future Investment Initiative conference, Elon Musk predicted that by 2040 there would be at least 10 billion humanoid robots, with each priced between $20,000 and $25,000.

Do the math. According to Musk, this technology could be worth $250 trillion by 2040.

Put another way, that’s roughly equal to:

  • 175 Teslas
  • 107 Amazons
  • 140 Metas
  • 84 Googles
  • 65 Microsofts
  • And 55 Nvidias

And here’s the wild part — this $250 trillion wave isn’t tied to one company, but to an entire ecosystem of AI innovators set to reshape the global economy.

It’s a leap so massive, it could reshape how businesses, governments, and consumers operate worldwide.

Even if that $250 trillion figure sounds ambitious, major firms like PwC and McKinsey still see AI unlocking multi-trillion-dollar potential.

How could anything be worth that much?

The answer lies in a breakthrough so powerful it’s redefining how humanity works, learns, and creates.

And this breakthrough has already set off a frenzy among hedge funds and Wall Street’s top investors.

What most investors don’t realize is that one under-owned company holds the key to this $250 trillion revolution.

In fact, Verge argues this company’s supercheap AI technology should concern rivals.

Before I reveal the details, let’s talk about how some of the richest people on the planet are positioning themselves.

  • Bill Gates sees artificial intelligence as the “biggest technological advance in my lifetime,” more transformative than the internet or personal computer, capable of improving healthcare, education, and addressing climate change.
  • Larry Ellison — through Oracle, is spending billions on Nvidia chips and partnering with Cohere to embed generative AI across Oracle’s cloud and apps.
  • Warren Buffett — not known for tech hype — says this breakthrough could have a ‘hugely beneficial social impact.

When billionaires from Silicon Valley to Wall Street line up behind the same idea — you know it’s worth paying attention to.

Even as we admire what Tesla, Nvidia, Alphabet, and Microsoft have built, we believe an even greater opportunity lies elsewhere…

But the real story isn’t Nvidia — it’s a much smaller company quietly improving the critical technology that makes this entire revolution possible.

And judging by what I’m hearing from both Silicon Valley insiders and Wall Street veterans…

This prediction might not be bold at all:

A few years from now, you’ll wish you’d owned this stock.

The best part? You can discover everything about this company and its groundbreaking technology right now.

I’ve compiled everything you need to know about this groundbreaking company in a detailed, members-only report.

Trust me — you’ll want to read this report before putting another dollar into any tech stock.

For a ridiculously low price of just $9.99 a month, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single fast food meal!

Here’s what to do next:

1. Subscribe to our Premium Readership Newsletter for just $9.99 a month. (33% Off – was $14.99).

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a month later!

 

Wall Street calls this $3 stock a “Melting Ice Cube.” They said the same thing about BTI before it returned 90%.

Dr. Inan Dogan

Dr. Ian Dogan

Co-Founder and Research Director at Insider Monkey

My name is Inan Dogan. I’m the co-founder and Research Director of Insider Monkey. I have an important message for you today.

Since March 2017, my stock picks have returned 16.5% annually. Today, I’ve found an opportunity even bigger than my British American Tobacco call.

Two years ago, Wall Street wrote off British American Tobacco (BTI) as a “melting ice cube.” The stock had crashed 40% from its peak, and consensus said the business was dying.

We looked under the cover and realized they were wrong.

We alerted our subscribers, and BTI returned 90% in just 16 months.

Now if you had invested just $10,000 in BTI in June 2024, you’d be sitting on $19,000 in October 2025.

Today, we have identified a nearly identical pattern in a digital-first giant trading at $3.

While the market panics over a surface-level revenue decline, our PhD-led research shows management has actually surgically cut $100 million in waste to focus on high-margin growth.

This pattern is a hallmark of our 16.5% annual return track record. The current opportunity offers a 400% upside potential—dwarfing even our 90% BTI return.

Get the ticker for our new “Underdog” pick and the full BTI case study for just 99 cents.

This exclusive offer is for NEW newsletter subscribers ONLY! Join our Premium Readership Newsletter for only $0.99 and become part of a savvy investor community.!

This offer vanishes in 7 days, so don’t miss your chance to lock in market beating returnsSign up NOW! The monthly newsletter comes with a 30-day, no-risk money-back guarantee. This offer is available to the first 1000 new investors who respond.

Regular price $9.99/mo. Cancel anytime.

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $0.99.

2. Enjoy a month of ad-free browsing, exclusive access to our in-depth report on the Trump tariff and nuclear energy company as well as the revolutionary AI-robotics company, and the upcoming issues of our Premium Readership Newsletter.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Regular price $9.99/mo. Cancel anytime.